eszopiclone

Quick answers

What is eszopiclone?

Eszopiclone (brand Lunesta) is a non-benzodiazepine hypnotic (“Z-drug”) approved for insomnia, often used for sleep onset and sleep maintenance symptoms.

What is LUNESTA?

LUNESTA is a brand name for eszopiclone.

What is LUNESTA (eszopiclone) used for?

Label indications include: Insomnia (label).

What drug class is LUNESTA (eszopiclone)?

Non-Benzo Hypnotic.

What is the mechanism of action of LUNESTA (eszopiclone)?

Non-benzodiazepine hypnotic (“Z-drug”); GABA-A receptor positive allosteric modulator.

What strengths does LUNESTA (eszopiclone) come in?

Tablets: 1 mg, 2 mg, 3 mg.

General information

Dysgeusia (metallic/bitter taste) is common, and the lowest effective dose is typically used. Eszopiclone is often positioned as a time-limited adjunct to CBT-I and sleep hygiene. Short prescriptions with planned follow-up are common; complex sleep behaviors, next-day impairment, or unsafe nighttime behaviors generally prompt discontinuation.

Mechanism of action

Refer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.

• GABA-A receptor facilitation (non-benzodiazepine hypnotic class).

Metabolism & pharmacokinetics

• Rapid absorption with Tmax ~1 hour and terminal half-life ~6 hours (label).
• Extensively metabolized; CYP3A4 and CYP2E1 are involved (label).
• <10% of drug is excreted unchanged in urine (label).
• Next-day impairment risk increases in older adults and severe hepatic impairment; dosing is often conservative and safety is reassessed after initiation or dose changes.

Dosing & administration

• Typically taken immediately before bedtime, when able to remain in bed for a full night.
• Food can delay onset; when delayed onset is a concern, bedtime dosing is often separated from heavy meals. “Middle of the night” redosing is generally avoided.
• The lowest effective dose is typically used; maximum dosing is lower in severe hepatic impairment or with potent CYP3A4 inhibitors.
• Alcohol and other sedatives increase risk and are generally avoided; use is reassessed frequently, and open-ended refills are typically avoided.

Monitoring & labs

• Next-day impairment (driving, work, falls) after initiation and dose changes; dosing is adjusted or discontinued if safety is compromised.
• Complex sleep behaviors; when they occur, discontinuation is typical.
• Mood and suicidality in patients with depression or serious mental illness.
• If continued beyond a brief course, taper attempts and CBT-I reinforcement to reduce rebound insomnia.

Sources: FDA/DailyMed label; AASM insomnia guideline; evidence reviews.

Adverse effects

Interactions

• Alcohol and other CNS depressants (opioids, benzodiazepines, sedating antipsychotics) increase risk and are generally avoided.
• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) increase exposure—lower doses and oversedation monitoring are common; inducers (e.g., rifampin, carbamazepine, St. John’s wort) may reduce efficacy.
• Combining with other sedative-hypnotics increases risk and is generally avoided when possible; if combinations are unavoidable, lower starting doses and closer follow-up are commonly used to reduce falls and driving risk.

Other useful information

• CBT-I and sleep hygiene are first-line; eszopiclone is often used for short, clearly bounded courses with stop plans.
• Generally avoided in untreated sleep apnea or when nighttime wandering is a safety concern.
• In chronic insomnia, underlying drivers are often addressed rather than escalating hypnotic doses.
• Short prescriptions with planned follow-up are common; complex sleep behaviors, next-day impairment, or unsafe nighttime behaviors generally prompt discontinuation.

References